125 related articles for article (PubMed ID: 21617196)
1. Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity.
Stummvoll GH; Schmaldienst S; Smolen JS; Derfler K; Biesenbach P
Nephrol Dial Transplant; 2012 Feb; 27(2):618-26. PubMed ID: 21617196
[TBL] [Abstract][Full Text] [Related]
2. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.
Stummvoll GH; Aringer M; Smolen JS; Schmaldienst S; Jiménez-Boj E; Hörl WH; Graninger WB; Derfler K
Ann Rheum Dis; 2005 Jul; 64(7):1015-21. PubMed ID: 15640267
[TBL] [Abstract][Full Text] [Related]
3. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity.
Biesenbach P; Schmaldienst S; Smolen JS; Hörl WH; Derfler K; Stummvoll GH
Atheroscler Suppl; 2009 Dec; 10(5):114-21. PubMed ID: 20129388
[TBL] [Abstract][Full Text] [Related]
4. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
5. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers.
Akhter E; Burlingame RW; Seaman AL; Magder L; Petri M
Lupus; 2011 Oct; 20(12):1267-74. PubMed ID: 21813587
[TBL] [Abstract][Full Text] [Related]
6. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies.
Gutiérrez-Adrianzén OA; Koutouzov S; Mota RM; das Chagas Medeiros MM; Bach JF; de Holanda Campos H
J Rheumatol; 2006 Aug; 33(8):1538-44. PubMed ID: 16783863
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares.
Matrat A; Veysseyre-Balter C; Trolliet P; Villar E; Dijoud F; Bienvenu J; Fabien N
Lupus; 2011 Jan; 20(1):28-34. PubMed ID: 20943718
[TBL] [Abstract][Full Text] [Related]
9. [Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis].
Cai XY; Yang XY; Chen XH; Liang LQ; Guan MM; Qin SG; Fu JZ
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1436-9. PubMed ID: 15500738
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
11. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
12. Prolonged remission in systemic lupus erythematosus.
Urowitz MB; Feletar M; Bruce IN; Ibañez D; Gladman DD
J Rheumatol; 2005 Aug; 32(8):1467-72. PubMed ID: 16078321
[TBL] [Abstract][Full Text] [Related]
13. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
[TBL] [Abstract][Full Text] [Related]
14. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease.
Reichlin M; Broyles TF; Hubscher O; James J; Lehman TA; Palermo R; Stafford HA; Taylor-Albert E; Wolfson-Reichlin M
Arthritis Rheum; 1999 Jan; 42(1):69-75. PubMed ID: 9920016
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
[TBL] [Abstract][Full Text] [Related]
17. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
19. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
20. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
